These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 19998745)

  • 1. Analysis of the impact of the Uruguay Round Agreements Act on pharmaceutical patents.
    Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Beyer A; Visaria J
    Food Drug Law J; 2009; 64(1):171-81. PubMed ID: 19998745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patent first, ask questions later: morality and biotechnology in patent law.
    Bagley MA
    William Mary Law Rev; 2003 Dec; 45(2):469-547. PubMed ID: 15570677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-to-invent versus first-to-file: impact of the AIA.
    Rachinsky T; Sullivan C; Ghosh S; Resnick DS; Burton C; Armstrong M; Hanish JP; Sklan A
    Pharm Pat Anal; 2014 Jul; 3(4):353-9. PubMed ID: 25291309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Herbal drug patenting in India: IP potential.
    Sahoo N; Manchikanti P; Dey SH
    J Ethnopharmacol; 2011 Sep; 137(1):289-97. PubMed ID: 21640810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL
    Duke Law J; 2013 Feb; 62(5):1069-108. PubMed ID: 25330553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
    Srivastava D
    Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
    [No Abstract]   [Full Text] [Related]  

  • 9. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Hogan GF
    Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of America Invents Act on Biotech Intellectual Property.
    Murphy A; Stramiello M; Stroud J; Lewis S; Irving T
    Cold Spring Harb Perspect Med; 2015 Apr; 5(9):a020784. PubMed ID: 25918182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The application of the patent laws to the drug approval process.
    Coggio BD; Cerrito FD
    Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669
    [No Abstract]   [Full Text] [Related]  

  • 12. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
    McPhie DC
    Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
    [No Abstract]   [Full Text] [Related]  

  • 13. If it's regulated like a duck ... uncertainties in implementing the patent exceptions of the Drug Price Competition and Patent Term Restoration Act.
    Bloch DJ
    Food Drug Law J; 1999; 54(1):111-26. PubMed ID: 11758554
    [No Abstract]   [Full Text] [Related]  

  • 14. Patents for critical pharmaceuticals: the AZT case.
    Ackiron E
    Am J Law Med; 1991; 17(1-2):145-80. PubMed ID: 1877607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The errors of error testing: potential liability issues for medication error testing of pharmaceutical trademarks under U.S. law.
    Thomas JA
    Food Drug Law J; 2004; 59(2):325-37. PubMed ID: 15298014
    [No Abstract]   [Full Text] [Related]  

  • 16. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patent reform in the US: what's at stake for pharmaceutical innovation?
    Yancey A; Stewart CN
    Expert Opin Ther Pat; 2010 May; 20(5):603-8. PubMed ID: 20402544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new history and discussion of 180-day exclusivity.
    Korn DE; Lietzan E; Scott SW
    Food Drug Law J; 2009; 64(2):335-90. PubMed ID: 19999288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H
    Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
    [No Abstract]   [Full Text] [Related]  

  • 20. Patenting DNA.
    Bobrow M; Thomas S
    Curr Opin Mol Ther; 2002 Dec; 4(6):542-7. PubMed ID: 12596355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.